Clinically, breast cancer is classified into four major subtypes [luminal A and B, HER2, and triple-negative (TN)] based on the expression of hormone receptors, namely estrogen receptor (ER) and progesterone receptor, HER2, and the proliferation marker Ki67. This evidence concerns the gene MKI67 and breast carcinoma.